Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.

Survey results highlight the need for concerted action to guard against a fresh upsurge in the disease.

Myriam Mendila describes how Novartis continued supporting cancer patients and healthcare professionals during the pandemic.